Chronic obstructive pulmonary disease </span><span style="font-family:""><span style="font-family:Verdana;">(COPD) is a major chronic respiratory disease worldwide. Inflammat...Chronic obstructive pulmonary disease </span><span style="font-family:""><span style="font-family:Verdana;">(COPD) is a major chronic respiratory disease worldwide. Inflammatory cells reflect the </span><span style="font-family:Verdana;">inflammatory situation both in peripheral blood and induced sputum. </span></span><span style="font-family:""><span style="font-family:Verdana;">Their correlation has not been reported. </span><span style="font-family:Verdana;">The correlation between neutrophils (Neu), eosinophils (Eos), and lymphocyte (Lym) in induced sputum and that in peripheral blood of COPD </span><span style="font-family:Verdana;">patients was evaluated </span><span><span style="font-family:Verdana;">to explore the </span><span style="font-family:Verdana;">consistency of inflammatory cells in peripheral blood and induced sputum. Peripheral blood and induced sputum were collected from 437 </span><span style="font-family:Verdana;">patients with acute exacerbation of COPD</span></span><span style="font-family:Verdana;"> (AECOPD) who were hospitalized in the Department of respiratory and critical care medicine, Inner Mongolia People’s Hospital. </span><span style="font-family:Verdana;">The correlation analysis was performed by Spearman correlation analysis. </span><span style="font-family:Verdana;">The r</span><span style="font-family:Verdana;">atios of Neu, Eos, and Lym in induced sputum were (79.15 ± 22.60)%, (5.23 ± 12.74)%, and (1.69 ± 2.66)%. The ratios of </span><span style="font-family:Verdana;">Neu, Eos, and Lym in </span><span style="font-family:Verdana;">peripheral blood were (63.29 ± 11.44)%, (2.99 ± 3.60)%, and (25.16 ± 10.19)%. The results showed that the ratios of Neu and Eos in induced sputum were significantly correlated with the proportion of </span><span style="font-family:Verdana;">corresponding cells in peripheral blood (P < 0.05). </span><span style="font-family:Verdana;">There was no correlation between the ratio of Lym and Leu in induced sputum and corresponding cells in </span><span style="font-family:Verdana;">peripheral blood (P > 0.05). In patients with AECOPD, the tendency of Neu and Eos in induced sputum was </span><span style="font-family:Verdana;">consistent with the corresponding cells in peripheral blood. Neu and Eos in </span><span style="font-family:Verdana;">induced sputum and peripheral blood reflected the degree of inflammation to guide the individualized medication of patients.展开更多
Background:From early experience,some Traditional Chinese Medicine and Arbidol had effects of against COVID-19,infer that the combination of Liushen capsules and Arbidol may further increase the therapeutic.Methods/De...Background:From early experience,some Traditional Chinese Medicine and Arbidol had effects of against COVID-19,infer that the combination of Liushen capsules and Arbidol may further increase the therapeutic.Methods/Design:We conducted a randomized,blank parallel-controlled,open-label,multi-center,basal therapy-loaded design clinical trial.A total of 40 patients are going to be recruited after satisfying the criteria.Participants will be allocated randomly into the treatment group with the combination of Arbidol and Liushen capsules and the control group with the basic therapy.Each group will receive treatment at least 7-days or until the virus becomes negative,and visits after drug administration at day 3(visit 1),the day when the virus becomes negative(visit 2),day 7(visit 3),the day before discharge(visit 4)and day 28(visit 5),to collect their survival status and disease prognosis so that the efficacy and safety of a combination of Arbidol and Liushen capsule will be evaluated.Discussion:We described the protocol of the first clinical trial for treatment COVID-19 by using a combination of Arbidol and Liushen capsules.The results of this study will provide a basis for the design and sample size estimate of subsequent large-scale clinical trials.Trial registration:This study has been registered at Chinese clinical trial Registry(chictr.org.cn):ChiCTR2000029993.展开更多
In this paper we propose and analyze a backward differentiation formula(BDF)type numerical scheme for the Cahn-Hilliard equation with third order temporal accuracy.The Fourier pseudo-spectral method is used to discret...In this paper we propose and analyze a backward differentiation formula(BDF)type numerical scheme for the Cahn-Hilliard equation with third order temporal accuracy.The Fourier pseudo-spectral method is used to discretize space.The surface diffusion and the nonlinear chemical potential terms are treated implicitly,while the expansive term is approximated by a third order explicit extrapolation formula for the sake of solvability.In addition,a third order accurate Douglas-Dupont regularization term,in the form of−A_(0)△t^(2)△_( N)(φ^(n+1)−φ^(n)),is added in the numerical scheme.In particular,the energy stability is carefully derived in a modified version,so that a uniform bound for the original energy functional is available,and a theoretical justification of the coefficient A becomes available.As a result of this energy stability analysis,a uniform-in-time L_(N)^(6)bound of the numerical solution is obtained.And also,the optimal rate convergence analysis and error estimate are provided,in the L_(△t)^(∞)(0,T;L_(N)^(2))∩L^(2)_(△ t)(0,T;H_(h)^(2))norm,with the help of the L_(N)^(6)bound for the numerical solution.A few numerical simulation results are presented to demonstrate the efficiency of the numerical scheme and the third order convergence.展开更多
文摘Chronic obstructive pulmonary disease </span><span style="font-family:""><span style="font-family:Verdana;">(COPD) is a major chronic respiratory disease worldwide. Inflammatory cells reflect the </span><span style="font-family:Verdana;">inflammatory situation both in peripheral blood and induced sputum. </span></span><span style="font-family:""><span style="font-family:Verdana;">Their correlation has not been reported. </span><span style="font-family:Verdana;">The correlation between neutrophils (Neu), eosinophils (Eos), and lymphocyte (Lym) in induced sputum and that in peripheral blood of COPD </span><span style="font-family:Verdana;">patients was evaluated </span><span><span style="font-family:Verdana;">to explore the </span><span style="font-family:Verdana;">consistency of inflammatory cells in peripheral blood and induced sputum. Peripheral blood and induced sputum were collected from 437 </span><span style="font-family:Verdana;">patients with acute exacerbation of COPD</span></span><span style="font-family:Verdana;"> (AECOPD) who were hospitalized in the Department of respiratory and critical care medicine, Inner Mongolia People’s Hospital. </span><span style="font-family:Verdana;">The correlation analysis was performed by Spearman correlation analysis. </span><span style="font-family:Verdana;">The r</span><span style="font-family:Verdana;">atios of Neu, Eos, and Lym in induced sputum were (79.15 ± 22.60)%, (5.23 ± 12.74)%, and (1.69 ± 2.66)%. The ratios of </span><span style="font-family:Verdana;">Neu, Eos, and Lym in </span><span style="font-family:Verdana;">peripheral blood were (63.29 ± 11.44)%, (2.99 ± 3.60)%, and (25.16 ± 10.19)%. The results showed that the ratios of Neu and Eos in induced sputum were significantly correlated with the proportion of </span><span style="font-family:Verdana;">corresponding cells in peripheral blood (P < 0.05). </span><span style="font-family:Verdana;">There was no correlation between the ratio of Lym and Leu in induced sputum and corresponding cells in </span><span style="font-family:Verdana;">peripheral blood (P > 0.05). In patients with AECOPD, the tendency of Neu and Eos in induced sputum was </span><span style="font-family:Verdana;">consistent with the corresponding cells in peripheral blood. Neu and Eos in </span><span style="font-family:Verdana;">induced sputum and peripheral blood reflected the degree of inflammation to guide the individualized medication of patients.
基金This work was supported by the Science research project of the Guangdong Province[Grant No.2020B111110001]Guangzhou Medical University High-level University Clinical Research and Cultivation Program(Guangzhou Medical University released[2017]No.159,160).
文摘Background:From early experience,some Traditional Chinese Medicine and Arbidol had effects of against COVID-19,infer that the combination of Liushen capsules and Arbidol may further increase the therapeutic.Methods/Design:We conducted a randomized,blank parallel-controlled,open-label,multi-center,basal therapy-loaded design clinical trial.A total of 40 patients are going to be recruited after satisfying the criteria.Participants will be allocated randomly into the treatment group with the combination of Arbidol and Liushen capsules and the control group with the basic therapy.Each group will receive treatment at least 7-days or until the virus becomes negative,and visits after drug administration at day 3(visit 1),the day when the virus becomes negative(visit 2),day 7(visit 3),the day before discharge(visit 4)and day 28(visit 5),to collect their survival status and disease prognosis so that the efficacy and safety of a combination of Arbidol and Liushen capsule will be evaluated.Discussion:We described the protocol of the first clinical trial for treatment COVID-19 by using a combination of Arbidol and Liushen capsules.The results of this study will provide a basis for the design and sample size estimate of subsequent large-scale clinical trials.Trial registration:This study has been registered at Chinese clinical trial Registry(chictr.org.cn):ChiCTR2000029993.
基金supported in part by the Computational Physics Key Laboratory of IAPCAM(P.R.China)under Grant 6142A05200103(K.Cheng)the National Science Foundation(USA)under Grant NSF DMS-2012669(C.Wang)Grants NSF DMS-1719854,DMS-2012634(S.Wise).
文摘In this paper we propose and analyze a backward differentiation formula(BDF)type numerical scheme for the Cahn-Hilliard equation with third order temporal accuracy.The Fourier pseudo-spectral method is used to discretize space.The surface diffusion and the nonlinear chemical potential terms are treated implicitly,while the expansive term is approximated by a third order explicit extrapolation formula for the sake of solvability.In addition,a third order accurate Douglas-Dupont regularization term,in the form of−A_(0)△t^(2)△_( N)(φ^(n+1)−φ^(n)),is added in the numerical scheme.In particular,the energy stability is carefully derived in a modified version,so that a uniform bound for the original energy functional is available,and a theoretical justification of the coefficient A becomes available.As a result of this energy stability analysis,a uniform-in-time L_(N)^(6)bound of the numerical solution is obtained.And also,the optimal rate convergence analysis and error estimate are provided,in the L_(△t)^(∞)(0,T;L_(N)^(2))∩L^(2)_(△ t)(0,T;H_(h)^(2))norm,with the help of the L_(N)^(6)bound for the numerical solution.A few numerical simulation results are presented to demonstrate the efficiency of the numerical scheme and the third order convergence.
